Nozomi Niitsu
- Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment 64
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research 22
- Neurology top 2%
- CNS Lymphoma Diagnosis and Treatment 16
- Oncology top 5%
- Viral-associated cancers and disorders 14
- Peptidase Inhibition and Analysis 13
- Hematology top 5%
- Acute Myeloid Leukemia Research 17
-
- Retinoids in leukemia and cellular processes 14
- Mechanisms of cancer metastasis 13
- Co-authors
- Masanori UmedaYoshio HonmaMasataka OkamotoHirokazu NakamineMasami HiranoIkuo MiuraMasanori OkamotoJunko Okabe‐Kado
- Partner nations
- JapanUnited StatesSouth Korea
In The Last Decade
Nozomi Niitsu
116 papers receiving 2.4k citations
Peers
Comparison fields: 5 of 86
- Pathology and Forensic Medicine 1.5k
- Genetics 608
- Neurology 556
- Oncology 969
- Hematology 235
Countries citing papers authored by Nozomi Niitsu
This map shows the geographic impact of Nozomi Niitsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nozomi Niitsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nozomi Niitsu more than expected).
Fields of papers citing papers by Nozomi Niitsu
This network shows the impact of papers produced by Nozomi Niitsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nozomi Niitsu. The network helps show where Nozomi Niitsu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Nozomi Niitsu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 7 | |
| 2 | 2010 | 9 | |
| 3 | 2010 | 21 | |
| 4 | 2010 | 80 | |
| 5 | 2008 | 1 | |
| 6 | 2008 | 17 | |
| 7 | 2006 | 6 | |
| 8 | 2006 | 10 | |
| 9 | 2006 | 10 | |
| 10 | 2002 | 19 | |
| 11 | 2002 | 70 | |
| 12 | Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine. | 2001 | 13 |
| 13 | 2001 | 9 | |
| 14 | びまん性大細胞型B細胞リンパ腫(DLBCL)における血清可溶性インターロイキン2受容体(sIL-2R)レベル:重要な予後因子 | 2000 | 2 |
| 15 | 2000 | 29 | |
| 16 | High levels of serum CD44 are correlated with poor prognosis in malignant lymphoma. | 1999 | 1 |
| 17 | 1998 | 7 | |
| 18 | [Clinical usefulness of 123I-BMIPP (beta-methyl iodophenyl pentadecanoic (acid) myocardial SPECT in patients with hematological malignancies with adriamycin-induced cardiomyopathy]. | 1996 | 0 |
| 19 | 1995 | 9 | |
| 20 | [Chronic daily administration of oral etoposide in elderly relapse or refractory lymphoma]. | 1994 | 1 |
About Nozomi Niitsu
Nozomi Niitsu is a scholar working on Pathology and Forensic Medicine, Genetics and Hematology, having authored 120 papers that have together received 2.5k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (64 papers), Chronic Lymphocytic Leukemia Research (22 papers), Acute Myeloid Leukemia Research (17 papers), CNS Lymphoma Diagnosis and Treatment (16 papers), Viral-associated cancers and disorders (14 papers), Retinoids in leukemia and cellular processes (14 papers), Peptidase Inhibition and Analysis (13 papers) and Mechanisms of cancer metastasis (13 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.5k citations), Genetics (608 citations) and Neurology (556 citations). Nozomi Niitsu has collaborated with scholars based in Japan, United States and South Korea. Frequent co-authors include Masanori Umeda, Yoshio Honma, Masataka Okamoto, Hirokazu Nakamine, Masami Hirano, Ikuo Miura, Masanori Okamoto, Junko Okabe‐Kado, Kimiko Iijima and Masaaki Hirano. Their work appears in journals such as Journal of Clinical Oncology, Blood and Oncogene.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.